Immunology and Microbiology
Hepatitis B
100%
Citrobacter Rodentium
81%
Hepatitis B Virus
78%
Mouse
78%
Hepatitis B Antigen
75%
HBsAg
75%
T Cell
71%
Immune Response
55%
Infectious Agent
53%
Macrophage
52%
Tumor Necrosis Factor
49%
Memory T Cell
41%
Vaccine Efficacy
39%
Complement
35%
Tumor-Associated Macrophage
35%
Cell Function
35%
Adipokine
35%
Complement Component C1q
35%
RIG-I
35%
Polyinosinic:polycytidylic Acid
35%
Child Health
35%
Colon
35%
Upregulation
35%
Homeobox
35%
Progeny
35%
Natural Killer Cell
35%
Exosome
35%
Intestine Flora
35%
Tight Junction
35%
CD8
35%
Enteritis
35%
Vaccine Adjuvant
35%
Escherichia coli
35%
STAT1
35%
Microflora
23%
Immunotherapy
23%
Knockout Mouse
20%
Type Three Secretion System
18%
interferon
17%
Wild Type
15%
Enterohemorrhagic Escherichia Coli
12%
Enteropathogenic Escherichia Coli
12%
Monospecific Antibody
12%
Bacteriolysis
11%
Complement Membrane Attack Complex
11%
Dendritic Cell
10%
Surface Property
10%
Inflammatory Bowel Disease
9%
Immune System
8%
Sustained Drug Release
8%
Keyphrases
T Cells
46%
NF-B
40%
PD-1 Blockade
35%
Proline Derivatives
35%
Influenza Neuraminidase Inhibitor
35%
Tumor
35%
STAT1 Signaling
35%
Chemoimmunotherapy
35%
RIG-G
35%
C1q/TNF-related protein-3
35%
Adipokines
35%
Bacterial Genotoxins
35%
UshA
35%
Natural Killer Cell Activity
35%
Sal-like Protein 4
35%
Exosomal
35%
Oseltamivir Derivatives
35%
Tumor Sensitization
35%
Hepatocellular Carcinoma
35%
Checkpoint Inhibitors
35%
Homeobox Containing 1
35%
T Cell Exhaustion
35%
Supramolecular Hydrogel
35%
MiR-146a
35%
MiR-146a-5p
35%
Negatively Regulate
35%
Intestinal Inflammation
35%
Tumor-associated
35%
Sirtuin 1 (SIRT1)
35%
M2 Macrophages
35%
Infiltration
35%
Exosomes
25%
Tumor Recurrence
17%
Immune Activation
17%
Sustained Release
17%
Depot
17%
Clinical Benefit
17%
Immune-related Adverse Events
17%
EspF
17%
Promising Strategies
17%
Camptothecin
17%
Anticancer
17%
In Situ Formation
17%
Tumor Regression
17%
Anticancer Drugs
17%
Immune Checkpoint Blockade
17%
Drug Delivery
17%
T Cell Immune Response
17%
Systemic Administration
17%
Therapeutic Effect
17%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
83%
Sialidase Inhibitor
59%
Camptothecin
56%
Immunotherapy
53%
Malignant Neoplasm
52%
Prodrug
35%
Chitosan
35%
Interferon
35%
Hepatitis B
35%
Nanogel
35%
Carcinogenesis
35%
Hepatitis B Antigen
35%
Sialidase
35%
Influenza A Virus (H5N1)
35%
Oseltamivir
35%
Influenza A (H5N1)
35%
Proline Derivative
35%
Proline
35%
Infection
33%
Mouse
32%
Tavokinogene Telseplasmid
27%
Tumor Recurrence
26%
Tumor Regression
26%
Tumor Microenvironment
26%
Programmed Death 1 Receptor
23%
4 Acetamido 5 Amino 3 (1 Ethylpropoxy) 1 Cyclohexene 1 Carboxylic Acid
23%
Infectious Agent
21%
Adverse Event
20%
Citrobacter Rodentium
14%
IC50
11%
Binding Site
11%
Metastasis
11%
Immunosuppressive Agent
10%
Metastasis Potential
8%
Sustained Release
8%
Anticarcinogen
8%
Systemic Administration
8%
Therapeutic Effect
8%
Peramivir
7%
Hydroxyproline
7%
Colon Cancer
7%
Enteropathogenic Escherichia Coli
7%
Enterohemorrhagic Escherichia Coli
7%
Pathogenesis
7%
Bacterial Infection
7%
Inflammation
7%
Colon Tumor
7%
Adenosine Phosphate
5%
Neuropilin 1
5%
Nanotube
5%
